Scarica l'app Stockscreener
10.51
0.65%
-0.069
Precedente Chiudi:
$10.58
Aprire:
$10.65
Volume 24 ore:
456
Relative Volume:
0.00
Capitalizzazione di mercato:
$524.49M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-15.63
EPS:
-0.6724
Flusso di cassa netto:
-
1 W Prestazione:
-13.63%
1M Prestazione:
-25.03%
6M Prestazione:
-18.27%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$10.65
$10.65
Intervallo di 1 settimana:
$10.50
$12.26
Portata 52W:
$8.75
$17.82
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Nome
Agomab Therapeutics Nv Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare AGMB vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGMB
Agomab Therapeutics Nv Adr
|
10.65 | 521.04M | 0 | 0 | 0 | -0.6724 |
VRTX
Vertex Pharmaceuticals Inc
|
521.37 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.46 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.13 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.68 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.17 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-03 | Iniziato | JP Morgan | Overweight |
| 2026-03-03 | Iniziato | Leerink Partners | Outperform |
| 2026-03-03 | Iniziato | Morgan Stanley | Overweight |
Agomab Therapeutics Nv Adr Borsa (AGMB) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
AgomAb Therapeutics Director Patel Naimish Receives Derivative Securities Award Equaling 100% of Holdings - Kalkine Media
AgomAb Therapeutics Director Marino Garcia Granted 57,482 Stock Options - Kalkine Media
Agomab Moves Inhaled IPF Drug AGMB-447 Into Phase 2 After Positive Phase 1 Results - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Agomab Shareholders Approve New Board Members and Pre-IPO Warrant Adjustment - TipRanks
ETFs Investing in AgomAb Therapeutics NV ADR Stocks - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS) - The Globe and Mail
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Agomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - The Globe and Mail
B.Riley initiates Agomab Therapeutics stock with buy rating - Investing.com India
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), COMPASS Pathways (CMPS) and Alkermes (ALKS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView
AGMB Forecast — Price Target — Prediction for 2027 - TradingView
Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com
Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com
Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.
Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate
Double BottomStock ScreenerCharts - Finviz
Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail
AgomAb (NASDAQ: AGMB) posts €62.5m loss and funds operations into 2029 - Stock Titan
AGMB Technical Analysis | Trend, Signals & Chart Patterns | AGOMAB THERAPEUTICS NV (NASDAQ:AGMB) - ChartMill
United Health Group, Viacom among market cap stock movers on Tuesday - Investing.com
World Map - Finviz
Reviewing Prime Medicine (NASDAQ:PRME) and AgomAb Therapeutics (NASDAQ:AGMB) - Defense World
Agomab receives U.S. patent for lung fibrosis drug candidate By Investing.com - Investing.com India
Agomab receives U.S. patent for lung fibrosis drug candidate - Investing.com
What is the current Price Target and Forecast for AgomAb Therapeutics NV (AGMB) - Zacks Investment Research
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Livemint
AgomAb Therapeutics NVADR (AGMB) sentiment score, message volume, participation score and buzz level - Stocktwits
AGMB: AgomAb Therapeutics NVADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
AgomAb Therapeutics NV American Depositary Shares (AGMB) Stock Price Today: $13.51 - Gotrade
EQT Life Sciences-Backed AgomAb Falls 8% After $200 Million IPO - Bloomberg
AgomAb Therapeutics NV (AGMB) stock price, news, quote and history - Yahoo Finance UK
Agomab Therapeutics Nv Adr Azioni (AGMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.82%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):